FOSTER CITY, Calif.,
March 27, 2017 /PRNewswire/ --
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that
Wilson W. Cheung, Chief Financial
Officer, will present a corporate overview and business update at
the 16th Annual Needham Healthcare Conference at
5:00 pm ET on Tuesday, April 4, 2017, at the Westin NY Grand
Central Hotel in New York City.
To access the live audio webcast of the presentation, please log
on through a link located in the Investor Relations section of
SciClone's website at www.sciclone.com, under the Calendar of
Events tab. A replay of the webcast will be available one hour
after the conclusion of the live events.
About SciClone
SciClone Pharmaceuticals is a revenue-generating, specialty
pharmaceutical company with a substantial commercial business in
China and a product portfolio
spanning major therapeutic markets including oncology, infectious
diseases and cardiovascular disorders. SciClone's proprietary
lead product, ZADAXIN® (thymalfasin), is approved
in over 30 countries and may be used for the treatment of hepatitis
B (HBV), hepatitis C (HCV), and certain cancers, and as an immune
system enhancer, according to the local regulatory approvals. The
Company has successfully in-licensed and commercialized products
with the potential to become future market leaders and to drive the
Company's long-term growth, including DC Bead®, a novel treatment
for liver cancer now approved in China, and several other products in late
stage development in China.
Through its promotion business with pharmaceutical partners,
SciClone also markets multiple branded products in China which are therapeutically
differentiated. SciClone is a publicly-held corporation based in
Foster City, California, and
trades on the NASDAQ Global Select Market under the symbol SCLN.
For additional information, please visit www.sciclone.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "approximately" or the
negative of those words or other comparable words to be uncertain
and forward-looking. These statements are subject to risks and
uncertainties that are difficult to predict and actual outcomes may
differ materially. Please also refer to other risks and
uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements.
SciClone, SciClone Pharmaceuticals, the SciClone
Pharmaceuticals design, the SciClone logo and ZADAXIN are
registered trademarks of SciClone Pharmaceuticals, Inc. in
the United States and numerous
other countries.
Corporate
Contacts
|
|
|
|
Wilson W.
Cheung
|
Jane
Green
|
Chief Financial
Officer
|
Investors/Media
|
650.358.3434
|
650.358.1447
|
wcheung@sciclone.com
|
jgreen@sciclone.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sciclone-to-present-at-needham-healthcare-conference-on-april-4-2017-300429205.html
SOURCE SciClone Pharmaceuticals, Inc.